Wir sind mit live! Mehr erfahren

GRAIL Inc

GRAL

Börsenwert 5,26 Mrd. $

117,81 USD

-17,65

13,03 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

118,00

+0,19

0,16 %

1 Tag

-13,03 %

5 Tage

-14,26 %

1 Monat

56,85 %

3 Monate

63,72 %

6 Monate

138,14 %

Seit Jahresbeginn

32,56 %

1 Jahr

36,34 %

5 Jahre

762,45 %

10 Jahre

762,45 %

Profil: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Mitarbeiter: 910

Gesundheitswesen Diagnostik & Research

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 12,6 %

Neutral 85,5 %

Negativ 1,9 %

Schaeffers Research

11 Stocks Most Likely to See a Short Squeeze Rally

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.

11 Stocks Most Likely to See a Short Squeeze Rally

First-Class Amenity Kits Have Become Holy Grail Collectibles

For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.

First-Class Amenity Kits Have Become Holy Grail Collectibles

The Motley Fool

Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.

Grail's stock surged after a positive FDA panel vote. Insurer adoption is crucial for Galleri's success.

Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.

The Motley Fool

2 Growth Stocks to Buy in October

Grail's stock could skyrocket if the FDA approves Galleri. Veeva's life sciences CRM business is still growing at a steady rate.

2 Growth Stocks to Buy in October

24/7 Wall Street

Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase

Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into their prices, and figuring out which side each sits on changes everything about whether to buy.

Why CVS Is ‘Insanely Cheap,' ON Semi a Laggard Catching Up, and Grail Too Expensive to Chase

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence SUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain taking place Oct. 23-27, 2026.

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

The Motley Fool

Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?

Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.

Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?

Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms

An advisory panel to the US Food and Drug Administration handed Grail's Galleri blood test a milestone win last week, saying the early cancer detection test's potential benefits outweigh its risks and bringing it a step closer to approval.

Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms

The Motley Fool

3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

Grail's stock recently hit its all-time high. If the FDA approves Galleri, it still looks reasonably valued.

3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

Investors Business Daily

Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next.

Grail stock has catapulted, reaching a record high, as the FDA mulls its contender in the multibillion-dollar cancer detection market.

Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next.

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt